Onterris, Inc. Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Onterris, Inc. (ONT)

Sionna Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Sionna Therapeutics (SION)

Sionna Therapeutics told investors its SION-719 program was on track; the Phase 2a Trial Failed Key Endpoint and stock lost roughly 90% of its value.

Tenax Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Tenax Therapeutics (TENX)

Tenax Therapeutics shareholders were left holding a substantially lower-valued stock after the Phase 3 LEVEL readout for TNX-103 -- and those losses may carry legal rights.

Onterris, Inc. Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Onterris, Inc. (ONT)

Onterris told investors regulatory changes would not meaningfully affect its business. A year later, the Company cited temporary regulatory waivers among the reasons for a 20% revenue decline -- and the stock fell roughly 18%.

N-able Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into N-able (NABL)

The investigation concerns whether N-able's public disclosures adequately reflected renewal trends across its UEM and EDR products before the Company reset its FY2026 revenue and ARR outlook.

Criteo Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Criteo (CRTO)

Criteo told investors adjusted EBITDA of $73 million for Q2 2026. Under GAAP, net income was $12 million -- down 49% year over year -- and the stock sold off the same day.